All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @thehonestattorney on TikTok · 35s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @thehonestattorney's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Stop taking Ozempic. People are suing and the side effects are terrifying. It's not just nausea
  2. 0:05anymore. Patients are filing lawsuits for paralysis of the stomach and some believe it's permanent.
  3. 0:10Ozempic and similar drugs like Manjaro are being linked to gastroparesis. A condition where your
  4. 0:15stomach literally stops working. That means vomiting food from days ago, intense pain and
  5. 0:21sometimes even feeding tubes. Plaintives say they were never worn and now they're living with
  6. 0:25permanent damage. So if you're taking Ozempic, don't ignore any new symptoms and talk to your
  7. 0:30doctor immediately. Send this to someone who's taking Ozempic before it's too late.

Does Ozempic deserve a blanket 'don't take it' warning?

The Honest Attorney

TikTok creator

13.3K viewsWatch on TikTok

Quick answer

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) slow gastric emptying as part of their mechanism of action, and a 2023 JAMA observational study by Sodhi et al. identified a statistically elevated incidence of gastroparesis diagnoses in GLP-1 users compared to a weight-loss drug comparator group. However, most reported GI adverse events in clinical practice appear to improve with dose reduction or discontinuation, and permanent gastroparesis attributable solely to GLP-1 use has not been established as a common or well-quantified outcome in peer-reviewed literature. Patients experiencing persistent GI symptoms should consult their prescriber before making any changes to their medication regimen.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Does Ozempic deserve a blanket 'don't take it' warning?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Does Ozempic deserve a blanket 'don't take it' warning?" from The Honest Attorney. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) slow gastric emptying as part of their mechanism of action, and a 2023 JAMA observational study by Sodhi et al.

The reason this review is not generic is the source wording and the canonical claim label "glp1 don t take ozempic period it s not a trend it s a drug with." In this clip, the useful excerpt is: "Stop taking Ozempic." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Most GI side effects associated with semaglutide, including delayed gastric emptying symptoms, appear to improve after dose reduction or stopping the drug, according to Camilleri (2023, Gut), undercutting the 'permanent damage' claim.
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) slow gastric emptying as part of their mechanism of action, and a 2023 JAMA observational study by Sodhi et al.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) slow gastric emptying as part of their mechanism of action, and a 2023 JAMA observational study by Sodhi et al. identified a statistically elevated incidence of gastroparesis diagnoses in GLP-1 users compared to a weight-loss drug comparator group. However, most reported GI adverse events in clinical practice appear to improve with dose reduction or discontinuation, and permanent gastroparesis attributable solely to GLP-1 use has not been established as a common or well-quantified outcome in peer-reviewed literature. Patients experiencing persistent GI symptoms should consult their prescriber before making any changes to their medication regimen.
  • A 2023 JAMA study (Sodhi et al.) found GLP-1 users had roughly 6x higher gastroparesis incidence per 1,000 person-years compared to a bupropion-naltrexone control group, but absolute numbers were small and causation was not established.
  • Most GI side effects associated with semaglutide, including delayed gastric emptying symptoms, appear to improve after dose reduction or stopping the drug, according to Camilleri (2023, Gut), undercutting the 'permanent damage' claim.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • A 2023 JAMA study (Sodhi et al.) found GLP-1 users had roughly 6x higher gastroparesis incidence per 1,000 person-years compared to a bupropion-naltrexone control group, but absolute numbers were small and causation was not established.
  • Most GI side effects associated with semaglutide, including delayed gastric emptying symptoms, appear to improve after dose reduction or stopping the drug, according to Camilleri (2023, Gut), undercutting the 'permanent damage' claim.
  • Gastroparesis is listed as a recognized risk in semaglutide prescribing information, so the claim that patients were entirely 'never warned' is not accurate, though litigation argues the warnings were inadequate.
  • The SELECT cardiovascular outcomes trial showed semaglutide reduced major adverse cardiovascular events by 20% in high-risk patients without diabetes, a benefit this video does not acknowledge.
  • The creator is a personal injury attorney whose firm is actively soliciting Ozempic-related cases, a direct financial conflict of interest that viewers should factor into how they weigh his framing.
  • Stopping a GLP-1 drug abruptly without medical guidance is not risk-free, particularly for patients using it to manage type 2 diabetes or obesity-related cardiovascular risk.
  • If you are experiencing persistent nausea, vomiting, or abdominal pain while on a GLP-1 medication, contact your prescriber. Dose titration adjustments are a standard clinical response to GI intolerance.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @thehonestattorney actually say?

A Florida injury attorney posted a TikTok telling viewers to "stop taking Ozempic" because "patients are filing lawsuits for paralysis of the stomach" and that the damage is "sometimes permanent." He linked semaglutide and tirzepatide ("Manjaro") to gastroparesis, described it as a condition where "your stomach literally stops working," and warned that plaintiffs claim they "were never warned" about the risk. He closed with an urgent call to send the video to anyone currently on the drug.

The hashtags included #druginjurylawyer and #schneiderinjuryfirm. This is not a neutral health educator. That context matters when you're parsing how he framed every sentence.

Does the science back this up?

Partially, but the framing is more alarming than the actual evidence justifies. There is a real signal here. The problem is how he characterized it.

A widely cited 2023 study by Sodhi et al. in JAMA found that GLP-1 receptor agonist users had a significantly higher risk of gastroparesis compared to users of bupropion-naltrexone. Specifically, the adjusted incidence rate for gastroparesis was roughly 9.09 per 1,000 person-years in GLP-1 users versus 1.53 for the comparator group. That is a real, statistically significant association.

However, the absolute numbers remain small, and this was an observational study, not a randomized trial. Causation has not been established. GLP-1 drugs slow gastric emptying by design. Whether that mechanism causes true, irreversible gastroparesis in a meaningful portion of patients, or whether pre-existing risk factors are doing the work, is still an open question. A 2023 analysis by Camilleri in Gut noted that most gastroparesis-like symptoms in GLP-1 users appear to resolve after stopping the drug, which directly contradicts the "permanent damage" framing.

What did they get wrong (or right)?

He got the existence of the risk basically right. He got the severity and permanence badly wrong, and that distinction is not a minor detail.

Calling this "paralysis of the stomach" that leads to "permanent damage" for a significant share of users is not what the current data shows. The word "paralysis" implies a dramatic, irreversible failure. What the studies show is delayed gastric emptying that, in a subset of patients, meets clinical criteria for gastroparesis. For most people who develop GI symptoms on semaglutide, those symptoms improve with dose reduction or discontinuation.

He also said patients "were never warned." That is the litigation framing, not the clinical framing. Gastroparesis and severe GI events are listed in semaglutide prescribing information, though critics argue the warnings were not prominent enough early on. That is a legitimate regulatory debate. Presenting it as a suppressed secret is a stretch.

To give credit where it is due: his advice to "not ignore any new symptoms and talk to your doctor" is sound. That part is accurate and responsible.

What should you actually know?

If you are taking semaglutide or tirzepatide, the gastroparesis association is real and worth knowing about. It is not a reason to panic or stop your medication without medical guidance, which is exactly the opposite of what this video recommends.

Blanket "don't take it" advice ignores that these drugs have demonstrated cardiovascular benefits in type 2 diabetes patients (the SELECT trial, Marso et al., 2016, NEJM), meaningful weight loss outcomes, and a risk-benefit profile that a physician, not a personal injury attorney, should be evaluating for each individual patient.

The FDA has been reviewing GLP-1-related GI adverse event reports and updated labeling. If you are experiencing persistent nausea, vomiting, or abdominal pain on a GLP-1 drug, you should contact your prescriber. Dose adjustments, slower titration, or switching agents are all options your doctor can discuss with you. Stopping abruptly without medical supervision can also carry risks, particularly for people managing type 2 diabetes.

The litigation wave is real. The lawsuits are real. But lawsuits are not the same as proven medical consensus, and an attorney with a firm hashtag in his bio has a financial interest in how alarming this story sounds.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

The Honest Attorney · TikTok creator

13.3K views on this video

Don’t take Ozempic. Period. 🚫 It’s not a trend — it’s a drug with serious risks. People are ending up with gastritis, stomach paralysis, and worse. And once you start? Quitting isn’t easy. No ifs. No ands. No buts. Don’t take it. 💬 Know someone using it? Tag them. Follow Justin Schneider | The Honest Attorney for legal tips that protect your health ✅ @thehonestattorney @thehonestattorney @thehonestattorney #DontTakeOzempic #OzempicSideEffects #DrugInjuryLawyer #TheHonestAttorney #Prescrip

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about a 2023 jama study (sodhi et al.) found glp-1 users?

A 2023 JAMA study (Sodhi et al.) found GLP-1 users had roughly 6x higher gastroparesis incidence per 1,000 person-years compared to a bupropion-naltrexone control group, but absolute numbers were small and causation was not established.

What does the video say about most gi side effects associated with semaglutide, including delayed gastric?

Most GI side effects associated with semaglutide, including delayed gastric emptying symptoms, appear to improve after dose reduction or stopping the drug, according to Camilleri (2023, Gut), undercutting the 'permanent damage' claim.

What does the video say about gastroparesis?

Gastroparesis is listed as a recognized risk in semaglutide prescribing information, so the claim that patients were entirely 'never warned' is not accurate, though litigation argues the warnings were inadequate.

What does the video say about the select cardiovascular outcomes trial showed semaglutide reduced major adverse?

The SELECT cardiovascular outcomes trial showed semaglutide reduced major adverse cardiovascular events by 20% in high-risk patients without diabetes, a benefit this video does not acknowledge.

What does the video say about the creator?

The creator is a personal injury attorney whose firm is actively soliciting Ozempic-related cases, a direct financial conflict of interest that viewers should factor into how they weigh his framing.

What does the video say about stopping a glp-1 drug abruptly without medical guidance?

Stopping a GLP-1 drug abruptly without medical guidance is not risk-free, particularly for patients using it to manage type 2 diabetes or obesity-related cardiovascular risk.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by The Honest Attorney, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.